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Abstract
Aims Increased glucose excursions and postprandial hyper-
glycaemia have been suggested as unique risk factors for
cardiovascular disease (CVD) and mortality in patients with
diabetes mellitus. Much of the evidence is based on a single
2 h glucose value after oral glucose tolerance testing in
epidemiological studies. We examined the association
between various indices of glycaemia measured during
everyday activities and metabolic CVD risk factors in the
A1C-Derived Average Glucose (ADAG) study.
Methods Participants (268 with type 1 diabetes, 159 with
type 2 diabetes) completed 16 weeks of intensive continuous
glucose monitoring (CGM) and self-monitoring of blood
glucose (SMBG). From these data, common indices of
postprandial glycaemia, overall hyperglycaemia, glucose
variability and HbA1c were derived. The associations
between glycaemic indices and known CVD risk factors
(lipids, high-sensitivity C-reactive protein and blood pres-
sure) were explored in linear regression models.
Results For both diabetes types, the overall strongest
associations with CVD risk factors were seen for the
measures of average glycaemia (mean blood glucose and
HbA1c). Associations between self-monitored postprandial
and fasting glucose and CVD risk factors were weaker, but
significant. Measurements of blood glucose variability
showed non-significant associations. Overall, calculations
based on CGM were not more informative than those based
on frequent SMBG.
Conclusions/interpretation Mean glycaemia and HbA1c
show consistent and stronger associations with CVD risk
factors than fasting glucose or postprandial glucose levels
or measures of glucose variability in patients with diabetes.
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Introduction
The role of postprandial hyperglycaemia and glucose
variability in relation to the risk of cardiovascular disease
(CVD) is heavily debated [1–4]. Treatment regimens and
guidelines have increasingly focused on the control of
postprandial glucose concentration (PPG) as an additional
target beyond average glucose (HbA1c) control. Much of
the evidence is based on single glucose concentration
values after oral glucose tolerance testing [5, 6]. Direct
evidence for an additional effect of controlling PPG
excursions, over and above an effect on reduced average
glucose levels, on relevant diabetic endpoints is limited.
The objective of this study was to examine the association
between different indices of glycaemia, monitored inten-
sively during daily life activities, and CVD risk factors in the
A1C-Derived Average Glucose (ADAG) study.
Methods
The ADAG study (2006–2008) defined the mathematical
relationship between HbA1c and average glucose levels,
and included 268 individuals with type 1 diabetes mellitus
and 159 with type 2 diabetes mellitus. A full description of
the ADAG study has been published previously [7]. The
study was approved by the human studies committees at the
participating institutions and informed consent was obtained
from all participants.
Continuous glucose monitoring (CGM) (Medtronic
Minimed, Northridge, CA, USA) was performed at baseline
and three times at 4 week intervals during the 12 week
study period. Monitoring lasted at least 48 h, during which
glucose levels were assessed every 5 min. Furthermore,
participants performed an eight-point profile of self-
monitored blood glucose (SMBG) (preprandial, 90 min
postprandial, bedtime and 03:00 hours) with a Hemocue
Glucose 201 Plus meter (Hemocue, Angelholm, Sweden)
during the days of CGM. During the weeks when CGM
was not performed, participants performed a seven-point
SMBG (preprandial, postprandial and bedtime) (OneTouch
Ultra; Lifescan, Milpitas, CA, USA) for at least 3 days per
week. All BG values stated are plasma equivalents.
The average BG concentration and SD were calculated
based on CGM data and the seven-point SMBG (Lifescan)
data. A combined average BG was calculated from CGM
and SMBG [7].
Two validated indices of intraday glucose variability
were calculated based on CGM: the mean amplitude of
glycaemic excursions (MAGE) and the continuous over-
lapping net glycaemic action (CONGA) [8, 9].
As an indicator of overall hyperglycaemia, the area under
the CGM curve (AUC) above levels of 7.8 or 11.1 mmol/l
(140 or 200 mg/dl) was calculated for the first 24 h of each
CGM monitoring period. Also, a postprandial AUC was
calculated for periods of 2 h after meals (without thresholds),
and a postprandial increment was calculated from the
preprandial glucose level to the highest peak within 2 h after
meals. Pre- and postprandial measurements from SMBG
(HemoCue) were used to calculate mean pre- and postprandial
BG, as well as pre- and post-breakfast, lunch and dinner values.
The pre-breakfast BG was used as fasting BG. All indices
based on CGMwere calculated after exclusion of the initial 2 h
of monitoring, considered to be the unstable calibration period.
HbA1c samples were analysed by DCCT-aligned assays;
the mean value at the end of the 12 week study period was
used [7]. Samples for lipids and high-sensitivity C-reactive
protein (hs-CRP) analyses were obtained at baseline (not
necessarily fasting) and analysed by validated methods at a
central laboratory (for details, see Electronic supplementary
material [ESM] Methods).
The associations of the calculated glycaemic indices
with the CVD risk factors were explored in separate linear
regression models adjusted for sex, age, smoking and
diabetes type. To facilitate comparison of associations,
glycaemic variables were standardised by the study popu-
lation SD. Each regression estimate represents the change
in the individual CVD risk factor per population SD change
in the explanatory variable. Non-standardised estimates are
given as examples in clinically relevant units.
In order to assess the combined cardiovascular risk, a
summed z score was calculated. CVD risk factors were
standardised (based on the distribution within each diabetes
type), and combined within the groups of lipids, blood
pressure, inflammation and anthropometrics (for details, see
ESM Methods). The z score was used as an additional
outcome variable in regression analyses with and without
stratification by diabetes type. The stratified estimates were
tested for interaction.
Results
Glucose monitoring was completed by 427 participants
with diabetes, leading to approximately 2,700 glucose
values per participant. We excluded one participant (type
1 diabetes mellitus) due to erroneous pre- and postprandial
Hemocue measurements.
Characteristics of the study population are summarised
in ESM Table 1.
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When examining the associations between different
glycaemic indices and known CVD risk factors, HbA1c
and mean BG consistently showed statistically significant
associations with the different risk factors with a larger
magnitude than most of the associations of the self-
monitored PPG measurements (ESM Table 2). PPG based
on CGM, fasting BG and overall hyperglycaemia also
showed statistically significant associations with CVD risk
factors, albeit at a lower level. Indices of glucose variability
and postprandial increment did not show significant
associations. A similar pattern of associations was present
for the various lipid measures, blood pressure and hs-CRP.
Adjustment for antihypertensive treatment or lipid lowering
medication, or exclusion of all participants with these
treatments, did not substantially alter the results.
Overall, the indices based on CGM were not more
informative than those based on frequent SMBG.
Higher levels of HbA1c were associated with higher
systolic blood pressure (2.2 mmHg per percentage unit
HbA1c), higher total cholesterol (0.1 mmol/l per percentage
unit HbA1c), higher hs-CRP (0.39 mg/ml per percentage
unit HbA1c) and lower HDL-cholesterol (0.04 mmol/l per
percentage unit HbA1c) (ESM Table 3)
The associations of the different glycaemic indices with
the combined CVD z score are illustrated in Fig. 1. Both for
the total group (in grey) and for the two diabetes types (in
black), the strongest associations were seen with the
measures of average glycaemia (mean BG and HbA1c)
and with the mean of all self-monitored postprandial BG
values. The difference between estimates for the two
diabetes types was not statistically significant (p values
between 0.15 and 0.92). The associations of the variability
indices with the CVD z score were not statistically
significant.
Discussion
We found that average glucose and HbA1c showed the
strongest associations with CVD risk factors among a wide
set of indicators of glycaemia and variability. Indices of
glycaemic variability showed no significant associations
with CVD risk factors.
Elevated postprandial glucose levels and/or glucose
variability have been suggested to increase the risk of CVD
beyond their effect on overall hyperglycaemia. Only a few
studies have tested this hypothesis directly or compared the
effect with that of overall glucose exposure (HbA1c) and
shown postprandial glucose levels and/or glucose variability
to be independent mechanisms. One single-blind randomised
trial comparing the effects of two insulin secretagogues with
different effects on PPG found that control of postprandial
hyperglycaemia led to a reduction in carotid intima–media
thickness in patients with type 2 diabetes compared with the
control group [1]. Therapy with lower PPG levels was
associated with significant reductions in the concentrations
of the inflammatory markers IL6 and hs-CRP. However, a
recent randomised clinical trial in patients with type 2
diabetes mellitus and CVD did not support an added benefit
of targeting control of PPG for subsequent CVD events [4].
In our study, glucose variability and postprandial hyper-
glycaemia did not have a stronger association with known
metabolic CVD risk factors than measures of average
glucose. This suggests that the impact of PPG on cardio-
vascular risk is likely to be captured by the assessment of
average blood glucose or HbA1c.
Several of the epidemiological studies demonstrating an
association between post-OGTT hyperglycaemia and in-
creased CVD and mortality did not take an average glucose
measurement (for example HbA1c) into account [2, 5].
In type 1 diabetes mellitus, glucose variability has not
been shown to be associated with the development of
complications. In the DCCT, BG variability (from seven-
point profiles) did not appear to be a factor in the
development of microvascular complications, and pre- and
postprandial glucose values contributed equally to small-
vessel complications [10].
The strength of this study is the analysis of glycaemia
under real-life circumstances in a large number of individ-
uals with diabetes. Intensive glucose monitoring using
several methods allowed us to compare several approaches
for defining PPG, and provided sufficient measurements to
reliably assess the different features of glycaemia.
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Fig. 1 Standardised associations between different glycaemic indices
and the z score derived from the CVD risk factors (associations per 1
population SD with 95% CI). Upper and lower black bars are for
patients with type 1 and type 2 diabetes mellitus, respectively; middle
grey bars are for both groups together (controlling for diabetes type).
Postprandial BG (AUC 2hpp CGM), area under the continuous
glucose monitoring curve 2 h postprandially; CONGA4, continuous
overlapping net glycaemic action (n=4 h); MAGE, mean amplitude of
glycaemic excursions
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The main limitation of the study is its cross-sectional
character. While it has a very high resolution, glucose
monitoring is short term and our outcomes are CVD risk
factors rather than actual CVD events. Therefore, although
we cannot reach direct conclusions regarding the impact of
postprandial glucose levels or glucose variability on CVD
endpoints, our results show that, if such an effect exists, it
is likely to be mediated through mechanisms other than
those examined in our study. The CVD risk factors we
chose are well-validated risk factors for CVD (lipids, blood
pressure and hs-CRP). Treatment to lower these CVD risk
factors might have confounded our findings.
The participants had stable HbA1c at baseline (defined as
a <1 percentage unit change in HbA1c during the 6 months
prior to the study), and were relatively stable during the
study. We may therefore have limited the range of glucose
variability as seen in a diabetic population. However, high
levels of glucose variability were seen among our individ-
uals despite stable HbA1c levels.
Our results do not support a unique role of postprandial
hyperglycaemia in CVD. Monitoring PPG and glucose
variability may be important in adjusting treatment to
achieve target mean glycaemia and to avoid daily excur-
sions, but our results suggest that interventions to reduce
the risk of CVD are best aimed at controlling mean glucose
and HbA1c.
We conclude that mean glycaemia and HbA1c show
stronger and consistent associations with CVD risk factors
than fasting glucose and most measures of postprandial
glucose and glucose variability. The previously observed
associations between glucose variability and postprandial
hyperglycaemia (often OGTT-based) and CVD events
cannot be explained by an association with CVD risk factors.
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